Ceritinib (LDK378) + Nivolumab
Phase 1Active 0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
ALK-positive NSCLC
Conditions
ALK-positive NSCLC
Trial Timeline
May 27, 2015 → Apr 9, 2027
NCT ID
NCT02393625About Ceritinib (LDK378) + Nivolumab
Ceritinib (LDK378) + Nivolumab is a phase 1 stage product being developed by Novartis for ALK-positive NSCLC. The current trial status is active. This product is registered under clinical trial identifier NCT02393625. Target conditions include ALK-positive NSCLC.
Hype Score Breakdown
Clinical
6
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02393625 | Phase 1 | Active |
Competing Products
9 competing products in ALK-positive NSCLC
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Crizotinib + Pembrolizumab | Merck | Phase 1 | 21 |
| Ceritinib | Novartis | Phase 2 | 27 |
| Ceritinib | Novartis | Phase 2 | 35 |
| ceritinib + warfarin + midazolam | Novartis | Phase 1 | 29 |
| PF-02341066 + Rifampin + Itraconazole | Pfizer | Phase 1 | 29 |
| Lortlatinib | Pfizer | Pre-clinical | 26 |
| Lorlatinib | Pfizer | Phase 2 | 31 |
| crizotinib + alectinib + brigatinib + ceritinib + lorlatinib | Pfizer | Pre-clinical | 26 |
| PF-06463922 + Crizotinib | Pfizer | Phase 1/2 | 32 |